Vifor Pharma AG (Vifor Pharma AG) Minority Interest : $520.30 Mil (As of Dec. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Vifor Pharma AG Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Vifor Pharma AG's minority interest for the quarter that ended in Dec. 2021 was $520.30 Mil.

Vifor Pharma AG Minority Interest Historical Data

The historical data trend for Vifor Pharma AG's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG Minority Interest Chart

Vifor Pharma AG Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Minority Interest

Get a 7-Day Free Trial

262.82

315.05

425.20

504.05

520.30

Vifor Pharma AG Semi-Annual Data
	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Minority Interest	Get a 7-Day Free Trial															425.20	398.93	504.05	431.59	520.30

Vifor Pharma AG Minority Interest Calculation

Vifor Pharma AG (Vifor Pharma AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (OTCPK:GNHAF) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rechenstrasse 37, Saint Gallen, CHE, 9014

Website

https://www.viforpharma.com

Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.